Varian, a Siemens Healthineers company, has launched its next generation microwave ablation solution, IntelliBlate, for the treatment of soft tissue tumours in Europe.
The CE mark-approved ablation solution provides a precision-driven, minimally invasive treatment option integrated with Siemens Healthineers’ imaging technologies.
It also offers clinicians enhanced predictability and control in treating soft tissue tumours.
IntelliBlate is designed to integrate seamlessly with Siemens Healthineers’ imaging and software solutions, including myAblation Guide, myNeedle and ultrasound systems.
The myAblation Guide is used for planning and post-procedural confirmation, while the myNeedle Laser guidance system is used for enhanced placement with CT scans.
The integration enables clinicians to plan, place, treat, monitor, and confirm ablation therapy within a single environment, simplifying workflows and boosting confidence.
Varian interventional solutions president Franck Facchini said: “The results of the COLLISION trial mark a milestone in how we think about ablation.
“We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery.
“IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.”
IntelliBlate is a compact and portable device that features two generators, and produces large, controlled spherical ablation zones for predictable outcomes.
Its key feature is the Ximitry probe, which includes thermocouples for continuous temperature monitoring both inside and outside the ablation zone.
The device enables clinicians to observe real-time temperature changes and make informed decisions during procedures.
Its intuitive interface, fast setup, and pre-set ablation zone settings simplify the process, reducing procedural barriers, making it a practical solution for various clinical needs.
The European launch of IntelliBlate follows the US Food and Drug Administration (FDA) market clearance, granted in 2024.
Varian plans to introduce IntelliBlate to the European clinical community in September, expanding access to advanced cancer treatment technologies across the region.
